Revance Therapeutics reported $285.33M in Current Assets for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Abbvie ABBV:US $ 26509M 1419M
Aerie Pharmaceuticals AERI:US $ 316.97M 38.68M
ALKERMES ALKS:US 1.01B 47.34M
Bristol Myers Squibb BMY:US $ 30121M 3141M
Cara Therapeutics CARA:US $ 151.76M 21.53M
Coherus Biosciences CHRS:US $ 512.44M 89.88M
Eli Lilly And LLY:US $ 16964.7M 1487.7M
Endo International Ordinary Shares ENDP:US $ 2492.79M 221.79M
Horizon Pharma HZNP:US $ 2947.73M 147.96M
JAZZ PHA JAZZ:US $ 2500.86M 110.48M
Johnson & Johnson JNJ:US $ 60424M 555M
Merk MRK:US $ 31184M 918M
Neurocrine Biosciences NBIX:US $ 1018.2M 45.4M
Pacira Pharmaceuticals PCRX:US $ 667.02M 199.03M
Procter & Gamble PG:US $ 23416M 2129M
Revance Therapeutics RVNC:US $ 285.33M 39.21M
Supernus Pharmaceuticals SUPN:US $ 568.52M 33.07M
Teva Pharmaceutical Industries TEVA:US $ 12451M 122M